ReWalk Robotics Hopes to Raise $50M in IPO
From Boston Herald:
A company with U.S. headquarters in Marlborough that was recently awarded FDA approval to sell its robotic exoskeletons for paraplegics plans to raise $50 million in an IPO this week, possibly on Friday.
Israeli-based ReWalk Robotics is planning to sell 3.5 million shares for between $14 and $16 each, which puts it at the low end of the 13 local health care companies which have gone public since the beginning of the year, more than any other year in history. Most of those have been biotech companies, however, making ReWalk the first robotics-focused company to do so in at least a couple of years... (cont'd)
Comments (0)
This post does not have any comments. Be the first to leave a comment below.
Featured Product
TUV Rheinland Robot Integrator Program
The industry's first comprehensive Robot Integrator Program saves robot integrators significant time and cost investments by allowing them to mark each cell compliant with ANSI/RIA R15.06 with the TUV Rheinland Mark. As opposed to a traditional certification or an on-site field labeling, TÜV Rheinland's Robot Integrator Program certifies the knowledge and skill-set of robot integrators in addition to testing robotic cells and processes against ANSI/RIA R15.06. This reduces the need for frequent onsite or off site testing and allows manufacturers to apply a single TÜV Rheinland label to multiple cells. The Robot Integrator Program individually assesses a robot integrator's understanding of the ANSI/RIA R15.06 standard along with the ability to consistently produce compliant robot cells. Following the requirements and procedures of the new program will enable robot integrators to produce individually compliant robotic cells under one serialized TÜV Rheinland Mark, which meets the national electric code and allows acceptance by Authorities Having Jurisdiction (AHJ) and end users.
